logo-loader
Shearwater Group PLC

Shearwater portfolio firm Xcina wins card data payment contract with FTSE 100-listed company

Shearwater said the contract award serves to highlight the applicability of Xcina’s information and cyber security solutions across corporate customers of all sizes

digital security
Sharewater said the initial contract award is worth £0.2mln to Xcina

Shearwater Group PLC (LON:SWG) has announced that its portfolio company Xcina has been appointed as an approved supplier of data and information assurance solutions to a global FTSE 100-listed firm.

In a statement, the AIM-listed company said Xcina has won an initial Payment Card Industry Data Security Standard (PCI DSS) architecture review contract worth £0.2mln.

The digital resilience group said Xcina’s work under this initial contract will help the customer to assess its PCI DSS card data payment environment with a view to ensuring that the customer meets its upcoming compliance audits in both the UK and US.

Read: Shearwater surges after buying award-winning data loss protection firm

Shearwater added that the contract serves to highlight the applicability of Xcina’s information and cyber security solutions across corporate customers of all sizes.

Michael Stevens, Shearwater's group chief executive officer commented: “This is an important milestone for Xcina and we are really pleased with the progress the company has made since we launched the business in July last year.

“Becoming an approved supplier to a global FTSE 100 company is testament to the quality of the Xcina team and the solutions the business is able to offer its continually expanding customer base.”

 

Quick facts: Shearwater Group PLC

Price: £0.02

Market: AIM
Market Cap: £40.34 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Open Orphan 'driving research for novel drug development for rare diseases'

Proactive London sits down with Open Orphan PLC's (LON:ORPH) chief operating officer Maurice Treacy. Treacy discusses how he became involved with Open Orphan and his ambitions for the firm's health data initiative. ''Many rare diseases aren't known or badly diagnosed ... but rare isn't...

14 hours, 44 minutes ago

2 min read